Psychoactive Drug Screening (PDSP)

NIMH PDSP的目的是提供新的合成化合物和天然产物的筛选， 作为基础和临床研究的研究工具或探针的潜在用途，作为精神障碍的治疗剂， 以及作为正电子发射断层扫描（PET）、单光子发射计算机断层扫描（SPECT）和功能断层扫描（FCT）。 磁共振成像（fMRI）配体用于功能性脑成像。 该程序主要用于筛选先前已显示具有 与NIMH相关的药理学，生物化学或行为活动，而不是为了大规模，随机 筛选天然产物或组合文库（例如，包含>1000种化合物的文库）。然而，在这方面， 筛选可以在活性未知的合成或天然产物化合物的小文库上进行， 通过NIH资助的高通量筛选（HTS）或化学项目产生的命中或先导化合物。

The purpose of the NIMH PDSP is to provide screening of novel synthetic compounds and natural products for potential use as research tools or probes for basic and clinical research, as therapeutic agents for mental disorders, and as positron emission tomography (PET), single photon emission computed tomography (SPECT), and functional magnetic resonance imaging (fMRI) ligands for functional brain imaging. This program is primarily intended as a screen for compounds that have previously been shown to possess pharmacological, biochemical, or behavioral activities relevant to NIMH and not for the purpose of large-scale, random screening of natural products or combinatorial libraries (e.g., libraries containing >1000 compounds). However, screening maybe conducted on small libraries of synthetic or natural product compounds of unknown activity and on hit or lead compounds generated through NIH-funded high throughput screening (HTS) or chemistry programs.